Global Anti-Obesity Prescription Drugs Sales Market Report 2020
Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.
Market Analysis and Insights: Global Anti-Obesity Prescription Drugs Market
The global Anti-Obesity Prescription Drugs market size is projected to reach US$ 719.1 million by 2026, from US$ 612.1 million in 2020, at a CAGR of 2.7% during 2021-2026.
Global Anti-Obesity Prescription Drugs Scope and Market Size
The global Anti-Obesity Prescription Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Obesity Prescription Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Anti-Obesity Prescription Drugs market is segmented into
Orlistat
Phentermine and Topiramate
Bupropion and Naltrexone
Lorcaserin
Liraglutide
Segment by Application, the Anti-Obesity Prescription Drugs market is segmented into
Pediatric
Adult
The Anti-Obesity Prescription Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Anti-Obesity Prescription Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Anti-Obesity Prescription Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Anti-Obesity Prescription Drugs business, the date to enter into the Anti-Obesity Prescription Drugs market, Anti-Obesity Prescription Drugs product introduction, recent developments, etc.
The major vendors covered:
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Market Analysis and Insights: Global Anti-Obesity Prescription Drugs Market
The global Anti-Obesity Prescription Drugs market size is projected to reach US$ 719.1 million by 2026, from US$ 612.1 million in 2020, at a CAGR of 2.7% during 2021-2026.
Global Anti-Obesity Prescription Drugs Scope and Market Size
The global Anti-Obesity Prescription Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Obesity Prescription Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Anti-Obesity Prescription Drugs market is segmented into
Orlistat
Phentermine and Topiramate
Bupropion and Naltrexone
Lorcaserin
Liraglutide
Segment by Application, the Anti-Obesity Prescription Drugs market is segmented into
Pediatric
Adult
The Anti-Obesity Prescription Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Anti-Obesity Prescription Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape
and Anti-Obesity Prescription Drugs Market Share AnalysisAnti-Obesity Prescription Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Anti-Obesity Prescription Drugs business, the date to enter into the Anti-Obesity Prescription Drugs market, Anti-Obesity Prescription Drugs product introduction, recent developments, etc.
The major vendors covered:
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
